Guardant Health director Tariq Musa sells $19,242 in stock

Guardant Health director Tariq Musa sold 116 shares of the company's common stock worth $19,242 on October 16, 2026. The shares were sold at $165.88 per share, slightly higher than the current trading price of $157.88. This sale occurred following the acquisition of 250 shares through the vesting of restricted stock units, acquired at no cost on October 15, 2026.

These shares were part of an award granted in March 2023, which vests over a four-year period, with initial vesting at 25% and the remaining 75% vesting monthly over the next three years. After these transactions, Mr. Musa holds 11,583 shares of Guardant Health common stock. Analysts predict the stock may be overvalued, with price targets ranging from $105 to $240.

Guardant Health reported a strong second-quarter revenue of $335 million, a 44% increase, surpassing market expectations. This success prompted the company to raise its year-end guidance. Competitors such as TD Cowen and Stifel raised their price targets, indicating confidence in the company's performance and product lineup. Despite this, some analysts maintain a cautious stance, suggesting the stock may be overvalued.